Vitamin K2 Supplementation and Vascular Calcification
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
Vascular calcification is the leading cause of death in patients with end stage renal disease
(ESRD) in hemodialysis. The protein matrix Gla vitamin K dependent (MGP) is a potent
inhibitor of the vascular calcification. Objective: To evaluate the effect of vitamin K2 on
vascular calcification in patients on hemodialysis. Materials and Methods: A prospective,
randomized, double-blind study will be performed. The study subjects will be divided into a
control (1000 µl of saline) or treated group (1000 µl containing 2000 µg of Vitamin K2).
Vitamin K2 will be administered three times a week intravenously at the end of each dialysis
session. Blood samples for biochemical determinations and vascular calcification will be
assessed before and after 6 months of treatment through carotid Doppler ultrasound.